Areas of focus include hematopoietic stem cells, hematopoietic growth factors and their receptors, leukemias and leukemogenesis, bone marrow failure syndromes, myeloproliferative syndromes, iron and heme metabolism, blood cell cytoskeleton biology, myeloid biology, transfusion medicine and gene therapy.
The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.
The membership panel is a list of chartered members only.
- Hematopoiesis, including hematopoietic stem and progenitor cells and epigenetic regulation of gene expression.
- Myelopoiesis, erythropoiesis, leukopoiesis and thrombopoiesis.
- Hemoglobin structure; blood substitutes; blood banking; development of globin gene regulation and transfusion medicine. Immunohematology.
- Iron and heme metabolism and iron overload states.
- Inherited or acquired anemias including sickle cell anemia, sideroblastic anemias, hemolytic anemias, anemia of chronic disease and anemias of bone marrow failure.
- Gene therapy of hematopoietic stem cells.
- Leukemias including myeloid leukemias, lymphocytic leukemias and lymphomas, and erythroleukemia.
- Bone marrow transplantation; stem cell transplantation; xenotransplantation and homing, migration, adhesion of hematopoietic stem cells.
Shared Interests and Overlaps
There are shared interests with Hemostasis and Thrombosis (HT) . Applications that contain sickle cell disease involving thrombosis may be assigned to HT. Applications involving sickle cell disease with a focus on red blood cells may be assigned to MCH.
There are shared interests with MCH . Applications focused on development of hematopoietic stem and progenitor cells during embryonic development are reviewed in Development-2 (DEV2). (NEW)
There are shared interests with Cancer Molecular Pathobiology (CAMP) / Molecular Oncogenesis (MONC) in blood cancers. Applications that focus on pre-leukemia and hematopoiesis in the leukemic environment may be assigned to MCH. Applications with a greater focus on oncogenic mechanisms may be assigned to either CAMP or MONC. (NEW)